Sign in
CompletedPhase 4

Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy

Key facts

Who runs it
University of Aarhus
Where
Denmark2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
71 people enrolled
Started
1 May 2018
Ended
21 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Prednisolone
  • Alfacalcidol
Record updated
24 January 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Biopsy proven minimal change nephropathy
  • If earlier minimal change: No relapse in 5 years, and earlier only treated with prednisolone
  • Nephrotic syndrome
  • Age more than 18 years

Who cannot take part

  • Cancer except from basal cells carcinoma
  • Lymphoproliferative disease
  • Allergy
  • eGFR < 30 ml/min/1,73m2 (CKD-EPI)
  • Pregnancy
  • No danish language
  • No ability to give informed prove

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Traditionally MCN is treated with a high dose of prednisolone, which induces remission in 60-90% of patients. Prednisolone treatment contains numerous side effects and the current dose is empiric. Given the lack of efficacy evidence and the risk associated with the currently accepted treatment regimen there is a need to characterize the outcome in MCN further, and to establish new, and potentially less toxic treatment regimens.

Read full original descriptionShow less

The aim is to examine if treatment with reduced dose of prednisolone in combination with activated vitamin D is as effective as standard high dose prednisolone in achieving remission and preventing relapse in MCN, and if reduced dose prednisolone is associated with fewer side effects compared to standard dose. Furthermore, the study will examine the influence of prednisolone metabolism on the efficacy and side effects of prednisolone in the treatment of MCN.

The 2 groups in the trial

  • High dose prednisoloneExisting treatment, for comparison

    Prednisolone 1 mg/kg/day

    Treatment: Prednisolone

  • Alfacalcidol and low dose prednisoloneTreatment being tested

    Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day

    Treatment: Prednisolone and Alfacalcidol

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D
Publications
Record updated
24 January 2025